西格列汀對(duì)2型糖尿病大鼠的骨保護(hù)作用與氧化應(yīng)激的關(guān)系
發(fā)布時(shí)間:2018-08-22 12:36
【摘要】:【目的】1.探討西格列汀干預(yù)對(duì)高脂高糖飲食聯(lián)合STZ誘導(dǎo)T2DM大鼠的骨密度、骨組織形態(tài)和骨轉(zhuǎn)換標(biāo)志物的影響;2.觀察西格列汀對(duì)T2DM大鼠的骨保護(hù)作用與氧化應(yīng)激的關(guān)系;3.探討西格列汀對(duì)T2DM大鼠的骨保護(hù)作用與p-ERK1/2/PPARγ表達(dá)的關(guān)系。【方法】1.構(gòu)建2型糖尿病大鼠模型:SD大鼠高脂高糖喂養(yǎng)8周,腹腔注射1%STZ(30mg/kg),連續(xù)3次空腹血糖≥16.7 mmol/L確認(rèn)為造模成功。2.西格列汀干預(yù):造模成功后,大鼠隨機(jī)分正常組(NC組)、2型糖尿病組(T2DM組)和2型糖尿病西格列汀干預(yù)組(SIT組)(均n=10)。SIT組予以西格列汀灌胃干預(yù)20周,其余大鼠予以生理鹽水灌胃。3.相關(guān)指標(biāo)檢測(cè):常規(guī)法測(cè)量血糖、體重;行腹腔注射葡萄糖耐量實(shí)驗(yàn)(IPGTT),并計(jì)算曲線下面積(AUC);放射免疫法檢測(cè)血清胰島素(INS);雙能X線骨密度儀(DEXA)檢測(cè)骨密度;HE染色行股骨組織形態(tài)學(xué)檢測(cè);酶聯(lián)免疫吸附法檢測(cè)OCN和TRACP-5b;AMP緩沖液法檢測(cè)ALP。5.相關(guān)基因及蛋白的檢測(cè):應(yīng)用RT-PCR及Western Blot法分別檢測(cè)大鼠股骨成骨細(xì)胞p-ERK1/2、PPARγ、p47phox、Bcl-2和Bax m RNA及蛋白表達(dá)水平�!窘Y(jié)果】1.造模成功糖尿病大鼠血糖明顯高于NC組(p0.05),平均空腹血糖達(dá)(18.46±1.67)mmol/L,血清INS水平低于NC組(p0.05)。2.西格列汀干預(yù)20周后,T2DM和SIT組血糖明顯高于NC組(p0.05),SIT組血糖低于T2DM組(p0.05);T2DM組體重低于NC組(p0.05)。T2DM組和SIT組血清INS低于NC組(P0.05),SIT組血清INS高于T2DM組(P0.05)。行IPGTT后,T2DM組、SIT組各點(diǎn)血糖和AUC明顯高于NC組(P0.05);SIT組各點(diǎn)血糖和AUC在NC組和T2DM組之間,差異有統(tǒng)計(jì)學(xué)意義(P0.05)。3.T2DM組骨形成標(biāo)志物ALP和OCN表達(dá)低于NC組(p0.05),骨吸收標(biāo)志物TRACP-5b表達(dá)高于NC組(p0.05);SIT組ALP水平低于NC組(p0.05),高于T2DM組(p0.05);SIT組OCN表達(dá)高于T2DM組(p0.05),TRACP-5b表達(dá)低于T2DM組(p0.05)。T2DM組下肢和脊柱骨密度明顯低于NC組(p0.05),SIT組下肢骨密度明顯高于T2DM組(p0.05),SIT組脊柱骨密度介于NC組和T2DM組之間,無(wú)統(tǒng)計(jì)學(xué)意義(p0.05)。4.骨組織形態(tài)學(xué)分析:與NC組相比,T2DM組骨皮質(zhì)變薄,骨小梁排列紊亂,間距變寬,骨髓腔明顯擴(kuò)張,骨細(xì)胞數(shù)量減少,空缺骨陷窩細(xì)胞顯著增多。與T2DM組相比,SIT組骨板層次清晰,結(jié)構(gòu)致密,骨小梁排列整齊,間距略窄,骨髓腔變窄,骨細(xì)胞清晰完整,空缺骨陷窩細(xì)胞少見(jiàn)。5.T2DM組和SIT組大鼠股骨成骨細(xì)胞p-ERK1/2、PPARγ、p47phox和Bax/Bcl-2 m RNA和蛋白表達(dá)高于NC組(p0.05);SIT組p-ERK1/2、p47phox和Bax/Bcl-2表達(dá)低于T2DM組(p0.05),而PPARγm RNA和蛋白表達(dá)與T2DM組相比無(wú)明顯差異。【結(jié)論】1.西格列汀可有效降低T2DM大鼠空腹血糖,改善胰島功能;2.西格列汀可增加T2DM大鼠骨密度,改善骨組織微結(jié)構(gòu),促進(jìn)骨形成,抑制骨吸收;3.西格列汀對(duì)T2DM大鼠的骨保護(hù)作用可能與拮抗成骨細(xì)胞氧化應(yīng)激相關(guān)基因p-ERK1/2、p47phox、Bax/Bcl-2有關(guān);4.西格列汀的骨保護(hù)作用與T2DM大鼠成骨細(xì)胞PPARγ的表達(dá)無(wú)關(guān)。
[Abstract]:[objective] 1. To investigate the effects of siglitatin intervention on bone mineral density (BMD), bone morphology and bone turnover markers in T2DM rats induced by high fat and high glucose diet combined with STZ. To observe the relationship between the protective effect of siglitatin and oxidative stress in T2DM rats. To investigate the relationship between the bone protective effect of siglitatin on T2DM rats and the expression of p-ERK1/2/PPAR 緯. [methods] 1. A rat model of type 2 diabetes was established. The rats were fed with hyperlipidemia and high glucose for 8 weeks. 1%STZ (30mg/kg) was injected intraperitoneally. Fasting blood glucose 鈮,
本文編號(hào):2197121
[Abstract]:[objective] 1. To investigate the effects of siglitatin intervention on bone mineral density (BMD), bone morphology and bone turnover markers in T2DM rats induced by high fat and high glucose diet combined with STZ. To observe the relationship between the protective effect of siglitatin and oxidative stress in T2DM rats. To investigate the relationship between the bone protective effect of siglitatin on T2DM rats and the expression of p-ERK1/2/PPAR 緯. [methods] 1. A rat model of type 2 diabetes was established. The rats were fed with hyperlipidemia and high glucose for 8 weeks. 1%STZ (30mg/kg) was injected intraperitoneally. Fasting blood glucose 鈮,
本文編號(hào):2197121
本文鏈接:http://sikaile.net/yixuelunwen/nfm/2197121.html
最近更新
教材專著